J&J Stock Upgraded on Strong Drug Pipeline Outlook

Leerink Partners Upgrades J&J to Outperform

Leerink Partners has upgraded Johnson & Johnson stock from "Market Perform" to "Outperform," setting a new 12-month price target of $265. This new target represents an approximate 18% upside from the stock's recent closing price, signaling strong confidence from the brokerage.

Growth Driven by New Drug Pipeline

The upgrade is based on accelerating growth prospects fueled by a wave of new drug launches. Analysts point to the company's expanding oncology and immunology franchises as key drivers. Four products—Icotyde, Inlexzo, Rybrevant, and Tremfya—are specifically highlighted as leading this new period of expansion for the pharmaceutical giant.

Financial Projections Exceed Consensus

Reflecting this optimism, Leerink now forecasts Johnson & Johnson's revenue to achieve a compound annual growth rate (CAGR) of 7.2% between 2026 and 2031. This projection is notably higher than the current Wall Street consensus expectation of approximately 6% for the same period, suggesting potential for significant market outperformance.

Outlook Summary

The positive revision from Leerink Partners underscores the potential of J&J's robust drug pipeline to deliver stronger-than-anticipated revenue growth. Investor focus will likely shift towards the performance and market adoption of these new key products in the coming quarters.

FAQ

Q: Why was Johnson & Johnson's stock upgraded?
A: The stock was upgraded due to accelerating growth prospects driven by new drug launches and expanding oncology and immunology franchises.

Q: What is the new price target for J&J according to Leerink?
A: The new 12-month price target is $265, which implies an approximate 18% upside from its recent close.

Source: Investing.com